Company

Xaira Therapeutics, Inc.

Xaira Therapeutics applies AI and machine learning to drug discovery and therapeutic development.

About

Xaira Therapeutics combines machine learning research, data generation, and therapeutic development to discover treatments. Its AI platform uses generative AI to design molecular structures and develop drug candidates. Founded in 2023 by Joe (Joe Watchwell) Watson, Buwei Huang, Nathaniel Bennett, and Philip Leung, the company is based in California, US, and was led by CEO Marc Tessier-Lavigne as of 2024. In April 2024, it raised USD 1 billion in venture funding co-led by Arch Venture Partners and Foresite Capitali, with participation from F-Prime, New Enterprise Associates, Sequoia Capital, Lux Capital, Lightspeed Venture Partners, Menlo Ventures, Two Sigma Investments, Parker Institute for Cancer Immunotherapy, Byers Capital, rSquared CRE, LLC, and SV Angel.

2Funding rounds

12Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in